Sanders Morris Harris LLC Sells 125,882 Shares of biote Corp. (NASDAQ:BTMD)

Sanders Morris Harris LLC reduced its position in biote Corp. (NASDAQ:BTMD) by 69.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 55,083 shares of the company’s stock after selling 125,882 shares during the quarter. Sanders Morris Harris LLC’s holdings in biote were worth $330,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BTMD. Dimensional Fund Advisors LP increased its holdings in biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after buying an additional 600,956 shares during the period. Renaissance Technologies LLC grew its holdings in shares of biote by 251.8% during the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after purchasing an additional 138,200 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of biote by 8.4% during the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after purchasing an additional 107,792 shares during the last quarter. State Street Corp grew its holdings in shares of biote by 13.7% during the 3rd quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after purchasing an additional 57,290 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of biote by 24.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock valued at $1,520,000 after purchasing an additional 54,302 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

biote Trading Down 0.5 %

NASDAQ:BTMD traded down $0.03 during mid-day trading on Thursday, hitting $5.91. 12,228 shares of the company’s stock were exchanged, compared to its average volume of 79,715. The company has a 50 day simple moving average of $6.16 and a 200-day simple moving average of $6.23. biote Corp. has a fifty-two week low of $3.65 and a fifty-two week high of $8.44. The firm has a market capitalization of $321.15 million, a P/E ratio of 22.73 and a beta of 1.08.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of biote in a report on Monday, December 16th. They set a “buy” rating and a $12.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, biote currently has a consensus rating of “Buy” and an average price target of $9.11.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.